<DOC>
	<DOCNO>NCT02329769</DOCNO>
	<brief_summary>The purpose study see whether PRO044 safe effective use medication Duchenne Muscular Dystrophy ( DMD ) patient mutation around location 44 DNA dystrophin protein .</brief_summary>
	<brief_title>Open Label , Extension Study PRO044 Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>A Phase II , open-label , extesion study . Following Screening period one month , subject previously treat PRO044 , eligible enrolment PRO044-CLIN-02 , allocate one three group receive either 6 mg/kg 9 mg/kg PRO044 weekly IV infusion 6 mg/kg weekly SC injection 48 week . Safety tolerability , pharmacokinetics ( PK ) , pharmacodynamic ( PD ) efficacy assessment conduct regular interval throughout study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Subjects previously treat PRO044 . 2 . Continued use glucocorticoid minimum 60 day prior study entry reasonable expectation subject remain steroids duration study . Changes dose regimen cessation glucocorticoid discretion Principle Investigator ( PI ) consultation subject/parent Medical Monitor . If subject steroid , involvement study need discuss medical monitor 1 . Current , history , liver renal disease . 2 . Acute illness within 4 week prior first dose PRO044 ( Week 1 ) may interfere measurement . 3 . Severe cardiac myopathy opinion Investigator prohibit participation study 4 . Need daytime mechanical ventilation . 5 . Screening aPTT upper limit normal ( ULN ) . 6 . Screening platelet count lower limit normal ( LLN ) . 7 . Use anticoagulant , antithrombotics antiplatelet agent . 8 . Use investigational product within 6 month prior start Screening study . 9 . Current history drug and/or alcohol abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>BioMarin</keyword>
	<keyword>PRO044</keyword>
</DOC>